Dense breasts: what it means, breast screening and what the research shows

Breast density is a description of how a mammogram looks, not how the breast feels. Cancer Research UK explains that the term dense refers to the way breast tissue appears on an X-ray: fatty tissue appears transparent, while fibrous and glandular tissue appears white. Women with very dense breasts have more fibrous and glandular tissue and less fatty tissue than other women.

Density has nothing to do with the size or firmness of the breast, so you cannot tell by feeling them, and a small or soft breast can be dense on a mammogram. It is also usually only revealed when a woman goes for a mammogram. Density varies naturally between women, and the UK NSC states that about 10% of women have very dense breasts and up to 50% have some mixed dense and fatty tissue, so it is a common finding, not a disease.

There are two reasons. The first is masking. The UK NSC says very dense breast tissue shows up on mammograms as white or opaque, making tumours harder to detect, and that screening can miss some cancers, particularly in women who have dense breast tissue. Cancer Research UK says that this lowers the chances of cancers being found early, when treatment is most likely to be successful.

The second is risk. Cancer Research UK says that between the ages of 50 and 70, women with very dense breasts are up to four times more likely to develop breast cancer than women with low breast density. The UK NSC says its 2019 review found a strong link between higher breast density and an increased risk of breast cancer, as well as a reduction in the effectiveness of mammograms when density is high.

These facts need to be kept in proportion. Most women with dense breasts will not develop breast cancer, density is one of several risk factors and it is not a symptom. The aim of understanding density is to ensure that screening is as effective as it can be and that any new breast changes are checked promptly.

The UK NSC says the UK breast screening programme invites women every 3 years from the age of 50 up to their 71st birthday. The digital mammography test takes pictures of each breast from 2 angles, and screening helps catch breast cancer, reducing the chance of death from the condition by 20%, according to the Committee.

The standard screening test is the same for everyone. The UK NSC explains that in 2019 it looked at whether offering extra ultrasound after a standard mammogram could help women with dense breasts, and concluded it could not yet be recommended, for two reasons: there was no standard test for dense breasts, so the same woman might get different results from different tests, and ultrasound can lead to many false positive results that incorrectly indicate cancer. It can find some cancers that mammograms miss, but there was no clear evidence that it lowered the chances of dying from breast cancer.

Since 2019 breast imaging has moved quickly. The UK NSC notes that in 2022 the European Society of Breast Imaging suggested people should be made aware of their breast density and that those with very dense breasts should be offered additional MRI screening, and that from September 2024 the US Food and Drug Administration mandated that mammogram reports include information on density. The UK NSC said in May 2025 that it was reviewing the latest evidence, including recent UK studies, to assess whether more imaging options could be added to the breast screening pathway for those with dense breasts, and that it planned to publish a report and next steps. Check the UK NSC website for the current position, as this is an area in which policy may change.

The key UK study is the BRAID trial, described by Cancer Research UK. Over 9,000 women joined the trial, led from the University of Cambridge and Addenbrooke's Hospital. After mammograms showed none had signs of breast cancer, 6,000 participants also received one of three additional scans, which picked up 85 cancers that had previously been missed. The two most effective techniques were contrast-enhanced mammography (CEM), which found an extra 19 cancers per 1,000 women, and abbreviated MRI (AB-MRI), which found an extra 17 per 1,000, compared with an average of 8 cancers per 1,000 detected by mammograms alone in women with dense breasts. Automated whole breast ultrasound also found cancers but was three times less effective. The results suggest that adding CEM or AB-MRI could help screening detect three times more cancers in women with dense breasts than it does today.

The charity stresses that more research is needed. The next step is to investigate whether using the additional scans as part of screening will reduce the number of people dying from breast cancer, and it notes that cancers detected through screening are not always life-threatening, so it is also important to make sure that adding new screening tests does not result in unnecessary treatment.

A normal screening mammogram does not mean you can ignore a new change. The NHS says to see a GP if you have a lump or swelling in your breast, chest or armpit, any changes in your breasts or nipples that are not normal for you, or pain in your breast or armpit and other people in your family have had breast or ovarian cancer. It also lists skin dimpling, a change in skin colour, a change in size or shape, nipple discharge and a change in the look of the nipple among the symptoms of breast cancer.

The NHS adds that some of these symptoms, including breast lumps, are very common and can be caused by other conditions, that having them does not definitely mean you have breast cancer, and that if symptoms are caused by cancer, finding it early may mean it is easier to treat. It encourages you to check your breasts regularly so you know what is normal for you.

On the NHS, screening follows the national programme described above and symptoms are assessed through the GP and a breast clinic. Some private providers offer additional scans or density reporting outside the screening programme. Because the evidence and policy are still developing, it is reasonable to ask a provider what the extra test adds, how it compares with standard screening, what its chance of false alarms is and how results will be shared with your GP and the screening service.